vs
NEUROCRINE BIOSCIENCES INC（NBIX）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是NEUROCRINE BIOSCIENCES INC的1.8倍（$1.4B vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -22.3%，领先41.4%），罗布乐思同比增速更快（43.2% vs 28.3%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $308.6M），过去两年罗布乐思的营收复合增速更高（32.9% vs 25.0%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
NBIX vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.8倍
$805.5M
营收增速更快
RBLX
高出14.9%
28.3%
净利率更高
NBIX
高出41.4%
-22.3%
自由现金流更多
NBIX
多$77.4M
$308.6M
两年增速更快
RBLX
近两年复合增速
25.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $1.4B |
| 净利润 | $153.7M | $-316.0M |
| 毛利率 | 97.8% | 77.7% |
| 营业利润率 | 26.2% | -25.3% |
| 净利率 | 19.1% | -22.3% |
| 营收同比 | 28.3% | 43.2% |
| 净利润同比 | 49.1% | -43.9% |
| 每股收益（稀释后） | $1.49 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBIXRBLX
| Q4 25 | $805.5M | $1.4B | ||
| Q3 25 | $794.9M | $1.4B | ||
| Q2 25 | $687.5M | $1.1B | ||
| Q1 25 | $572.6M | $1.0B | ||
| Q4 24 | $627.7M | $988.2M | ||
| Q3 24 | $622.1M | $919.0M | ||
| Q2 24 | $590.2M | $893.5M | ||
| Q1 24 | $515.3M | $801.3M |
净利润NBIXRBLX
| Q4 25 | $153.7M | $-316.0M | ||
| Q3 25 | $209.5M | $-255.6M | ||
| Q2 25 | $107.5M | $-278.4M | ||
| Q1 25 | $7.9M | $-215.1M | ||
| Q4 24 | $103.1M | $-219.6M | ||
| Q3 24 | $129.8M | $-239.3M | ||
| Q2 24 | $65.0M | $-205.9M | ||
| Q1 24 | $43.4M | $-270.6M |
毛利率NBIXRBLX
| Q4 25 | 97.8% | 77.7% | ||
| Q3 25 | 98.2% | 78.2% | ||
| Q2 25 | 98.4% | 78.2% | ||
| Q1 25 | 98.4% | 78.3% | ||
| Q4 24 | 98.5% | 77.9% | ||
| Q3 24 | 98.7% | 77.7% | ||
| Q2 24 | 98.4% | 77.8% | ||
| Q1 24 | 98.5% | 77.7% |
营业利润率NBIXRBLX
| Q4 25 | 26.2% | -25.3% | ||
| Q3 25 | 30.1% | -21.8% | ||
| Q2 25 | 21.2% | -29.8% | ||
| Q1 25 | 4.1% | -24.6% | ||
| Q4 24 | 22.6% | -24.7% | ||
| Q3 24 | 29.5% | -30.4% | ||
| Q2 24 | 24.6% | -26.6% | ||
| Q1 24 | 19.3% | -37.7% |
净利率NBIXRBLX
| Q4 25 | 19.1% | -22.3% | ||
| Q3 25 | 26.4% | -18.8% | ||
| Q2 25 | 15.6% | -25.8% | ||
| Q1 25 | 1.4% | -20.8% | ||
| Q4 24 | 16.4% | -22.2% | ||
| Q3 24 | 20.9% | -26.0% | ||
| Q2 24 | 11.0% | -23.0% | ||
| Q1 24 | 8.4% | -33.8% |
每股收益（稀释后）NBIXRBLX
| Q4 25 | $1.49 | $-0.44 | ||
| Q3 25 | $2.04 | $-0.37 | ||
| Q2 25 | $1.06 | $-0.41 | ||
| Q1 25 | $0.08 | $-0.32 | ||
| Q4 24 | $1.00 | $-0.32 | ||
| Q3 24 | $1.24 | $-0.37 | ||
| Q2 24 | $0.63 | $-0.32 | ||
| Q1 24 | $0.42 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $3.3B | $394.5M |
| 总资产 | $4.6B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资NBIXRBLX
| Q4 25 | $713.0M | $3.1B | ||
| Q3 25 | $340.2M | $2.9B | ||
| Q2 25 | $264.0M | $2.6B | ||
| Q1 25 | $194.1M | $2.7B | ||
| Q4 24 | $233.0M | $2.4B | ||
| Q3 24 | $349.1M | $2.3B | ||
| Q2 24 | $139.7M | $2.4B | ||
| Q1 24 | $396.3M | $2.4B |
总债务NBIXRBLX
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NBIXRBLX
| Q4 25 | $3.3B | $394.5M | ||
| Q3 25 | $3.0B | $407.6M | ||
| Q2 25 | $2.7B | $353.2M | ||
| Q1 25 | $2.5B | $310.7M | ||
| Q4 24 | $2.6B | $221.4M | ||
| Q3 24 | $2.7B | $189.9M | ||
| Q2 24 | $2.5B | $121.5M | ||
| Q1 24 | $2.4B | $71.6M |
总资产NBIXRBLX
| Q4 25 | $4.6B | $9.6B | ||
| Q3 25 | $4.3B | $8.6B | ||
| Q2 25 | $3.9B | $7.8B | ||
| Q1 25 | $3.7B | $7.5B | ||
| Q4 24 | $3.7B | $7.2B | ||
| Q3 24 | $3.5B | $6.7B | ||
| Q2 24 | $3.3B | $6.5B | ||
| Q1 24 | $3.5B | $6.3B |
负债/权益比NBIXRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $308.6M |
| 自由现金流率自由现金流/营收 | 47.9% | 21.8% |
| 资本支出强度资本支出/营收 | 0.3% | 21.1% |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $1.4B |
8季度趋势，按日历期对齐
经营现金流NBIXRBLX
| Q4 25 | $388.4M | $607.0M | ||
| Q3 25 | $227.5M | $546.2M | ||
| Q2 25 | $102.0M | $199.3M | ||
| Q1 25 | $64.8M | $443.9M | ||
| Q4 24 | $242.5M | $184.5M | ||
| Q3 24 | $158.0M | $247.4M | ||
| Q2 24 | $64.6M | $151.4M | ||
| Q1 24 | $130.3M | $238.9M |
自由现金流NBIXRBLX
| Q4 25 | $386.0M | $308.6M | ||
| Q3 25 | $214.3M | $443.6M | ||
| Q2 25 | $89.5M | $176.7M | ||
| Q1 25 | $54.1M | $426.5M | ||
| Q4 24 | $235.2M | $120.6M | ||
| Q3 24 | $149.9M | $218.0M | ||
| Q2 24 | $53.0M | $111.7M | ||
| Q1 24 | $119.1M | $192.3M |
自由现金流率NBIXRBLX
| Q4 25 | 47.9% | 21.8% | ||
| Q3 25 | 27.0% | 32.6% | ||
| Q2 25 | 13.0% | 16.3% | ||
| Q1 25 | 9.4% | 41.2% | ||
| Q4 24 | 37.5% | 12.2% | ||
| Q3 24 | 24.1% | 23.7% | ||
| Q2 24 | 9.0% | 12.5% | ||
| Q1 24 | 23.1% | 24.0% |
资本支出强度NBIXRBLX
| Q4 25 | 0.3% | 21.1% | ||
| Q3 25 | 1.7% | 7.5% | ||
| Q2 25 | 1.8% | 2.1% | ||
| Q1 25 | 1.9% | 1.7% | ||
| Q4 24 | 1.2% | 6.5% | ||
| Q3 24 | 1.3% | 3.2% | ||
| Q2 24 | 2.0% | 4.4% | ||
| Q1 24 | 2.2% | 5.8% |
现金转化率NBIXRBLX
| Q4 25 | 2.53× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RBLX
暂无分部数据
